Cellaria to Release Novel Ovarian and Breast Cancer Cell Models

Patient-specific cell models provide researchers with improved tools that relate directly to clinical conditions

Print
| Source: Cellaria Bio

CAMBRIDGE, Mass., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models for challenging tumors, today announced the release of two new ovarian cancer cell models and one breast cancer cell model. With these additions to its model library, Cellaria expands on its mission to provide researchers with more accurate models of the tumor, enabling more relevant and impactful research and accelerated discovery efforts.

By tying its models to clinical indications, Cellaria aims to ignite research innovation and step beyond traditional cell lines that overestimate drug efficacy and lack biological relevance. Of the two new ovarian models, one was derived from a patient with serous ovarian cancer, and the second cell model was derived from a patient with endometrioid ovarian cancer.

The new breast cancer cell model was developed from a patient with ER positive breast cancer. The cell models are heterogeneous and stable, using SNP genotyping to evaluate genomic stability with 85%-98% concordance between the patient tumor and the cell model. Cellaria’s Cell Models are supplied with a Certificate of Analysis that provides detailed lot-specific information about the expected growth rate, clinical history, and quality test results, including STR profiling for cell line authentication.

Earlier this year, the National Cancer Institute (NCI) announced that it was retiring the popular NCI 60 panel of human cancer cell lines, replacing it with a “rejuvenated repository of cancer models that are derived from fresh patient samples.” These samples would also be tagged with clinical information. As the global cancer research community adopts tools that are more representative of patients, Cellaria is setting the pace with its growing portfolio of patient-specific models.

“With the existing challenges in identifying oncology drug candidates that will be successful, pharmaceutical companies need improved models to target candidates with the highest chance of success in the clinic,” said David Deems, chief executive officer at Cellaria. “These unique cell models for ovarian and breast cancer will help scientists better understand drug response from heterogeneous patient populations and improve their research outcomes.”     

About Cellaria
Cellaria creates breakthrough oncology models that reflect the unique nature and complexity of a tumor. Using these informative models, cancer researchers are better able to select promising compounds and work towards personalized approaches that would enable physicians to identify the most effective treatment for each patient’s needs. Cellaria’s innovative products help lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cancer cure. For more information, visit www.cellariabio.com. You can learn more about our cell models here.

Contact:
Tim Walsh
for Cellaria Bio
617.512.1641